An Infectious cDNA Clone of SARS-CoV-2

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884

A novel coronavirus from patients with pneumonia in China, 2019

Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001017 · Cited by 28,244

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention

Wu, Z., & McGoogan, J. M. (2020) · JAMA · doi:10.1001/jama.2020.2648 · Cited by 17,016

First case of 2019 novel coronavirus in the United States

Holshue, M. L., DeBolt, C., Lindquist, S., Lofy, K. H., Wiesman, J., Bruce, H., Spitters, C., Ericson, K., Wilkerson, S., Tural, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001191 · Cited by 6,030

SARS and MERS: recent insights into emerging coronaviruses

de Wit, E., van Doremalen, N., Falzarano, D., & Munster, V. J. (2016) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2016.81 · Cited by 3,510

The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade

Coutard, B., Valle, C., de Lamballerie, X. N., Canard, B., Seidah, N. G., & Decroly, É. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104742 · Cited by 1,706

Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study

Assiri, A., Al-Tawfiq, J. A., Al-Rabeeah, A. A., Al-Rabiah, F. A., Al-Hajjar, S., Al-Barrak, A., Flemban, H., Al-Nassir, W. N., Balkhy, H. H., Al-Hakeem, R. F., et al. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70204-4 · Cited by 1,435

A bright monomeric green fluorescent protein derived from Branchiostoma lanceolatum

Shaner, N. C., Lambert, G. G., Chammas, A., Ni, Y., Cranfill, P. J. C., Baird, M. A., Sell, B., Allen, J. R., Day, R. N., Israelsson, M., et al. (2013) · Nature Methods · doi:10.1038/nmeth.2413 · Cited by 1,260

A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence

Menachery, V. D., Yount, B. L., Debbink, K. M., Agnihothram, S., Gralinski, L. E., Plante, J. A., Graham, R. L., Scobey, T., Ge, X., Donaldson, E., et al. (2015) · Nature Medicine · doi:10.1038/nm.3985 · Cited by 901

A Versatile Reporter System To Monitor Virus-Infected Cells and Its Application to Dengue Virus and SARS-CoV-2

Pahmeier, F., Neufeldt, C. J., Cerikan, B., Prasad, V. R., Pape, C., Laketa, V., Ruggieri, A., Bartenschlager, R. F. W., & Cortese, M. (2020) · Journal of Virology · doi:10.1128/jvi.01715-20 · Cited by 39

Mechanisms of SARS-CoV-2 neutralization by shark variable new antigen receptors elucidated through X-ray crystallography

Ubah, O. C., Lake, E. W., Gunaratne, G. S., Gallant, J. P., Fernie, M., Robertson, A. J., Marchant, J. S., Bold, T. D., Langlois, R. A., Matchett, W. E., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27611-y · Cited by 38

Pre-existing SARS-CoV-2 immunity influences potency, breadth, and durability of the humoral response to SARS-CoV-2 vaccination

Mantus, G. E., Nyhoff, L. E., Edara, V. V., Zarnitsyna, V. I., Ciric, C. R., Flowers, M. W., Norwood, C., Ellis, M. L., Hussaini, L., Manning, K. E., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100603 · Cited by 37

Engineering a Reliable and Convenient SARS-CoV-2 Replicon System for Analysis of Viral RNA Synthesis and Screening of Antiviral Inhibitors

Luo, Y., Yu, F., Zhou, M., Liu, Y., Xia, B., Zhang, X., Liu, J., Zhang, J., Du, Y., Li, R., et al. (2021) · mBio · doi:10.1128/mbio.02754-20 · Cited by 39

Versatile SARS-CoV-2 Reverse-Genetics Systems for the Study of Antiviral Resistance and Replication

Fahnøe, U., Pham, L. V., Fernandez-Antunez, C., Costa, R., Rivera-Rangel, L. R., Galli, A., Feng, S., Mikkelsen, L. S., Gottwein, J. M., Scheel, T. K. H., et al. (2022) · Viruses · doi:10.3390/v14020172 · Cited by 38

The RNA helicase DHX16 recognizes specific viral RNA to trigger RIG-I-dependent innate antiviral immunity

Hage, A., Bharaj, P., van Tol, S., Giraldo, M. I., González-Orozco, M., Valerdi, K. M., Warren, A. N., Aguilera-Aguirre, L., Xie, X., Widen, S. G., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110434 · Cited by 37

A protease-activatable luminescent biosensor and reporter cell line for authentic SARS-CoV-2 infection

Gerber, P. P., Duncan, L. M., Greenwood, E. J. D., Marelli, S., Naamati, A., Teixeira-Silva, A., Crozier, T. W. M., Gabaev, I., Zhan, J. R., Mulroney, T. E., et al. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010265 · Cited by 37

In Vitro Selection of Remdesivir-Resistant SARS-CoV-2 Demonstrates High Barrier to Resistance

Checkmahomed, L., Carbonneau, J., Pont, V. D., Riola, N. C., Perry, J. K., Li, J., Paré, B., Simpson, S. M., Smith, M. A., Porter, D., et al. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00198-22 · Cited by 38

The Translational Landscape of SARS-CoV-2-infected Cells Reveals Suppression of Innate Immune Genes

Puray‐Chavez, M., Lee, N., Tenneti, K., Wang, Y., Vuong, H. R., Liu, Y., Horani, A., Huang, T., Gunsten, S. P., Case, J. B., et al. (2022) · mBio · doi:10.1128/mbio.00815-22 · Cited by 49

Susceptibility to SARS-CoV-2 of Cell Lines and Substrates Commonly Used to Diagnose and Isolate Influenza and Other Viruses

Wang, L., Fan, X., Bonenfant, G., Cui, D., Hossain, J., Jiang, N., Larson, G. P., Currier, M., Liddell, J., Wilson, M. M., et al. (2021) · Emerging infectious diseases · doi:10.3201/eid2705.210023 · Cited by 38

Reverse genetics systems for SARS‐CoV‐2

Wang, W., Peng, X., Jin, Y., Pan, J., & Guo, D. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27738 · Cited by 36

Suppressing fatty acid synthase by type I interferon and chemical inhibitors as a broad spectrum anti-viral strategy against SARS-CoV-2

Aliyari, S. R., Ghaffari, A. A., Pernet, O., Parvatiyar, K., Wang, Y., Gerami, H., Tong, A.-J., Vergnes, L., Takallou, A., Zhang, A., et al. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.02.019 · Cited by 35

Bronchial epithelia from adults and children: SARS-CoV-2 spread via syncytia formation and type III interferon infectivity restriction

Beucher, G., Blondot, M.-L., Celle, A., Pied, N., Recordon-Pinson, P., Estèves, P., Faure, M., Métifiot, M., Lacomme, S., Dacheux, D., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2202370119 · Cited by 38

Determinants and Mechanisms of the Low Fusogenicity and High Dependence on Endosomal Entry of Omicron Subvariants

Qu, P., Evans, J. P., Kurhade, C., Zeng, C., Zheng, Y.-M., Xu, K. Y., Shi, P., Xie, X., & Liu, S. (2023) · mBio · doi:10.1128/mbio.03176-22 · Cited by 41

Generation of Recombinant SARS‐CoV‐2 Using a Bacterial Artificial Chromosome

Chiem, K., Ye, C., & Martínez‐Sobrido, L. (2020) · Current Protocols in Microbiology · doi:10.1002/cpmc.126 · Cited by 30

A PCR amplicon-based SARS-CoV-2 replicon for antiviral evaluation

Kotaki, T., Xie, X., Shi, P., & Kameoka, M. (2021) · Scientific Reports · doi:10.1038/s41598-021-82055-0 · Cited by 34

Comparison of anti-SARS-CoV-2 activity and intracellular metabolism of remdesivir and its parent nucleoside

Tao, S., Zandi, K., Bassit, L., Ong, Y. T., Verma, K., Liu, P., Downs-Bowen, J. A., McBrayer, T. R., LeCher, J. C., Kohler, J. J., et al. (2021) · Current Research in Pharmacology and Drug Discovery · doi:10.1016/j.crphar.2021.100045 · Cited by 34

Reverse genetic systems of SARS-CoV-2 for antiviral research

Kurhade, C., Xie, X., & Shi, P. (2022) · Antiviral Research · doi:10.1016/j.antiviral.2022.105486 · Cited by 36

Vaccination with SARS-CoV-2 Spike Protein and AS03 Adjuvant Induces Rapid Anamnestic Antibodies in the Lung and Protects Against Virus Challenge in Nonhuman PrimatesPreprint

Francica, J., Flynn, B., Foulds, K., Noe, A. T., Werner, A. P., Moore, I. N., Gagne, M., Johnston, T., Tucker, C., Davis, R. L., et al. (2021) · bioRxiv · doi:10.1101/2021.03.02.433390 · Cited by 35

Interferon-alpha or -beta facilitates SARS-CoV-2 pulmonary vascular infection by inducing ACE2

Klouda, T. M., Hao, Y. T., Kim, H., Kim, J. J., Olejnik, J., Hume, A. J., Ayyappan, S., Hong, X., Melero‐Martin, J. M., Fang, Y., et al. (2021) · Angiogenesis · doi:10.1007/s10456-021-09823-4 · Cited by 32

Resistance mechanisms of SARS-CoV-2 3CLpro to the non-covalent inhibitor WU-04

Zhang, L., Xie, X., Luo, H., Qian, R., Yang, Y., Yu, H., Huang, J., Shi, P., & Hu, Q. (2024) · Cell Discovery · doi:10.1038/s41421-024-00673-0 · Cited by 34

Discovery of re-purposed drugs that slow SARS-CoV-2 replication in human cells

Pickard, A., Calverley, B. C., Chang, J., Garva, R., Gago, S., Lu, Y., & Kadler, K. E. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009840 · Cited by 35

COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review

Simnani, F. Z., Singh, D., & Kaur, R. (2021) · 3 Biotech · doi:10.1007/s13205-021-03076-0 · Cited by 35

Variable susceptibility of intestinal organoid–derived monolayers to SARS-CoV-2 infection

Jang, K. K., Kaczmarek, M. E., Dallari, S., Chen, Y.-H., Tada, T., Axelrad, J. E., Landau, N. R., Stapleford, K. A., & Cadwell, K. (2022) · PLoS Biology · doi:10.1371/journal.pbio.3001592 · Cited by 34

Human Cardiac Pericytes Are Susceptible to SARS-CoV-2 Infection

Brumback, B. D., Dmytrenko, O., Robinson, A. N., Bailey, A. L., Ma, P., Liu, J., Hicks, S. C., Ng, S., Li, G., Zhang, D. M., et al. (2022) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2022.09.001 · Cited by 36

Impaired SARS-CoV-2 Variant Neutralization and CD8+ T-cell Responses Following 3 Doses of mRNA Vaccines in Myeloma: Correlation with Breakthrough Infections

Azeem, M. I., Nooka, A. K., Shanmugasundaram, U., Cheedarla, N., Potdar, S. V., Manalo, R. J., Moreno, A., Switchenko, J. M., Cheedarla, S., Doxie, D. B., et al. (2022) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-22-0173 · Cited by 31

Ubiquitin variants potently inhibit SARS-CoV-2 PLpro and viral replication via a novel site distal to the protease active site

van Vliet, V. J. E., Huynh, N., Palà, J., Patel, A., Singer, A. U., Slater, C., Chung, J., van Huizen, M., Teyra, J., Miersch, S., et al. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1011065 · Cited by 35

Unconventional secretion of unglycosylated ORF8 is critical for the cytokine storm during SARS-CoV-2 infection

Lin, X., Fu, B., Xiong, Y., Xing, N., Xue, W., Guo, D., Zaky, M. Y., Pavani, K. C., Kunec, D., Trimpert, J., et al. (2023) · PLoS Pathogens · doi:10.1371/journal.ppat.1011128 · Cited by 33

Mutations in SARS-CoV-2 variant nsp6 enhance type-I interferon antagonism

Bills, C. J., Xia, H., Chen, J. Y.-C., Yeung, J., Kalveram, B., Walker, D. H., Xie, X., & Shi, P. (2023) · Emerging Microbes & Infections · doi:10.1080/22221751.2023.2209208 · Cited by 33

A single dose of replication-competent VSV-vectored vaccine expressing SARS-CoV-2 S1 protects against virus replication in a hamster model of severe COVID-19

Malherbe, D. C., Kurup, D., Wirblich, C., Ronk, A. J., Mire, C. E., Kuzmina, N. A., Shaik, N. F., Periasamy, S., Hyde, M. A., Williams, J. M., et al. (2021) · npj Vaccines · doi:10.1038/s41541-021-00352-1 · Cited by 31

Global Diversification and Distribution of Coronaviruses With Furin Cleavage Sites

Liu, X., Wu, Q., & Zhang, Z. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.649314 · Cited by 32

An antibody that neutralizes SARS-CoV-1 and SARS-CoV-2 by binding to a conserved spike epitope outside the receptor binding motif

Fang, Y., Sun, P., Xie, X., Du, M., Du, F., Ye, J., Kalveram, B., Plante, J. A., Plante, K. S., Li, B., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abp9962 · Cited by 30

Rapid, dose-dependent and efficient inactivation of surface dried SARS-CoV-2 by 254 nm UV-C irradiation

Ruétalo, N., Businger, R., & Schindler, M. (2021) · Eurosurveillance · doi:10.2807/1560-7917.es.2021.26.42.2001718 · Cited by 31

Cross-neutralization of Omicron BA.1 against BA.2 and BA.3 SARS-CoV-2

Zou, J., Kurhade, C., Xia, H., Liu, M., Xie, X., Ren, P., & Shi, P. (2022) · Nature Communications · doi:10.1038/s41467-022-30580-5 · Cited by 28

Aspects of Nanotechnology for COVID-19 Vaccine Development and Its Delivery Applications

Prabhakar, P. K., Khurana, N., Vyas, M., Sharma, V., Batiha, G. E., Kaur, H., Singh, J., Kumar, D., Sharma, N., Kaushik, A. K., et al. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020451 · Cited by 32

The NSP4 T492I mutation increases SARS-CoV-2 infectivity by altering non-structural protein cleavage

Lin, X., Sha, Z., Trimpert, J., Kunec, D., Jiang, C., Xiong, Y., Xu, B., Zhu, Z., Xue, W., & Wu, H. (2023) · Cell Host & Microbe · doi:10.1016/j.chom.2023.06.002 · Cited by 32

DYRK1A promotes viral entry of highly pathogenic human coronaviruses in a kinase-independent manner

Strine, M. S., Cai, W. L., Wei, J., Alfajaro, M. M., Filler, R. B., Biering, S. B., Sarnik, S. A., Chow, R. D.-W., Patil, A., Cervantes, K. S., et al. (2023) · PLoS Biology · doi:10.1371/journal.pbio.3002097 · Cited by 29

Brain exposure to SARS-CoV-2 virions perturbs synaptic homeostasis

Partiot, E., Hirschler, A., Colomb, S., Lutz, W., Claeys, T., Delalande, F., Deffieu, M. S., Bare, Y., Roels, J. R. E., Gorda, B., et al. (2024) · Nature Microbiology · doi:10.1038/s41564-024-01657-2 · Cited by 33

Inactivated rabies virus vectored SARS-CoV-2 vaccine prevents disease in a Syrian hamster model

Kurup, D., Malherbe, D. C., Wirblich, C., Lambert, R., Ronk, A. J., Diba, L. Z., Bukreyev, A. A., & Schnell, M. J. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009383 · Cited by 30

Efficacy of mRNA-1273 and Novavax ancestral or BA.1 spike booster vaccines against SARS-CoV-2 BA.5 infection in nonhuman primates

Routhu, N. K., Stampfer, S. D., Lai, L., Akhtar, A., Tong, X., Yuan, D., Chicz, T. M., McNamara, R. P., Jakkala, K., Davis-Gardner, M. E., et al. (2023) · Science Immunology · doi:10.1126/sciimmunol.adg7015 · Cited by 28

Scalable, Micro-Neutralization Assay for Assessment of SARS-CoV-2 (COVID-19) Virus-Neutralizing Antibodies in Human Clinical Samples

Bennett, R. S., Postnikova, E. N., Liang, J. Y., Gross, R., Mazur, S., Dixit, S., Lukin, V. V., Kocher, G., Yu, S., Georgia, S., et al. (2021) · Viruses · doi:10.3390/v13050893 · Cited by 29

Human Immunodeficiency Viruses Pseudotyped with SARS-CoV-2 Spike Proteins Infect a Broad Spectrum of Human Cell Lines through Multiple Entry Mechanisms

Xu, C., Wang, A., Geng, K., Honnen, W. J., Wang, X., Bruiners, N., Singh, S., Ferrara, F., D’Angelo, S., Bradbury, A. M., et al. (2021) · Viruses · doi:10.3390/v13060953 · Cited by 30

Studying SARS-CoV-2 with Fluorescence Microscopy

Putlyaeva, L. V., & Lukyanov, K. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126558 · Cited by 27

A randomized study to evaluate safety and immunogenicity of the BNT162b2 COVID-19 vaccine in healthy Japanese adults

Haranaka, M., Baber, J., Ogama, Y., Yamaji, M., Aizawa, M., Kogawara, O., Scully, I. L., Lagkadinou, E., Türeci, Ö., Şahin, U., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27316-2 · Cited by 28

Spike protein-independent attenuation of SARS-CoV-2 Omicron variant in laboratory mice

Liu, S., Selvaraj, P., Sangare, K., Luan, B., & Wang, T. T. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111359 · Cited by 29

Structural and functional characteristics of the SARS-CoV-2 Omicron subvariant BA.2 spike protein

Zhang, J., Tang, W., Gao, H., Lavine, C. L., Shi, W. K., Peng, H., Zhu, H., Anand, K., Kosikova, M., Kwon, H. J., et al. (2023) · Nature Structural & Molecular Biology · doi:10.1038/s41594-023-01023-6 · Cited by 29

Antibody Response against SARS-CoV-2 and Seasonal Coronaviruses in Nonhospitalized COVID-19 Patients

Ruétalo, N., Businger, R., Althaus, K., Fink, S., Ruoff, F., Pogoda, M., Iftner, A., Ganzenmueller, T., Hamprecht, K., Flehmig, B., et al. (2021) · mSphere · doi:10.1128/msphere.01145-20 · Cited by 27

An intra-cytoplasmic route for SARS-CoV-2 transmission unveiled by Helium-ion microscopy

Merolli, A., Kasaei, L., Ramasamy, S., Kolloli, A., Kumar, R., Subbian, S., & Feldman, L. C. (2022) · Scientific Reports · doi:10.1038/s41598-022-07867-0 · Cited by 29

SARS‐CoV‐2 neutralization and serology testing of COVID‐19 convalescent plasma from donors with nonsevere disease

Gniadek, T. J., Thiede, J. M., Matchett, W. E., Gress, A. R., Pape, K. A., Fiege, J. K., Jenkins, M. K., Menachery, V. D., Langlois, R. A., & Bold, T. D. (2020) · Transfusion · doi:10.1111/trf.16101 · Cited by 28

Light Sheet Microscopy-Assisted 3D Analysis of SARS-CoV-2 Infection in the Respiratory Tract of the Ferret Model

Zaeck, L. M., Scheibner, D., Sehl‐Ewert, J., Müller, M., Hoffmann, D., Beer, M., Abdelwhab, E. M., Mettenleiter, T. C., Breithaupt, A., & Finke, S. (2021) · Viruses · doi:10.3390/v13030529 · Cited by 27

Tiled-ClickSeq for targeted sequencing of complete coronavirus genomes with simultaneous capture of RNA recombination and minority variants

Jaworski, E. A., Langsjoen, R. M., Mitchell, B. M., Judy, B. M., Newman, P. C., Plante, J. A., Plante, K. S., Miller, A. L., Zhou, Y., Swetnam, D. M., et al. (2021) · eLife · doi:10.7554/elife.68479 · Cited by 25

Stable Cell Clones Harboring Self-Replicating SARS-CoV-2 RNAs for Drug Screen

Liu, S., Chou, C., Wu, W. W., Luan, B., & Wang, T. T. (2022) · Journal of Virology · doi:10.1128/jvi.02216-21 · Cited by 27

An optimized circular polymerase extension reaction-based method for functional analysis of SARS-CoV-2

Liu, G., & Gack, M. U. (2023) · Virology Journal · doi:10.1186/s12985-023-02025-y · Cited by 26

Construction of Non-infectious SARS-CoV-2 Replicons and Their Application in Drug Evaluation

Wang, B., Zhang, C., Lei, X., Ren, L., Zhao, Z., Wang, J., & Huang, H. (2021) · Virologica Sinica · doi:10.1007/s12250-021-00369-9 · Cited by 27

SARS-CoV-2 serology testing: Progress and challenges

Shi, A. C., & Ren, P. (2021) · Journal of Immunological Methods · doi:10.1016/j.jim.2021.113060 · Cited by 28

CMPK2 restricts Zika virus replication by inhibiting viral translation

Pawlak, J. B., Hsu, J. C.-C., Xia, H., Han, P., Suh, H., Grove, T. L., Morrison, J. M., Shi, P., Cresswell, P., & Laurent-Rolle, M. (2023) · PLoS Pathogens · doi:10.1371/journal.ppat.1011286 · Cited by 25

Emerging Human Coronavirus Infections (SARS, MERS, and COVID-19): Where They Are Leading Us

Kumar, V. (2020) · International Reviews of Immunology · doi:10.1080/08830185.2020.1800688 · Cited by 29

SARS-CoV-2 Infection: Host Response, Immunity, and Therapeutic Targets

Shivshankar, P., Karmouty‐Quintana, H., Mills, T., Doursout, M., Wang, Y., Czopik, A. K., Evans, S. E., Eltzschig, H. K., & Yuan, X. (2022) · Inflammation · doi:10.1007/s10753-022-01656-7 · Cited by 28

The S protein of a novel recombinant PEDV strain promotes the infectivity and pathogenicity of PEDV in mid‐west China

Liu, H., Yin, X., Tian, H., Qiu, Y., Wang, Z., Chen, J., Ma, D., Zhao, B., Du, Q., Tong, D., et al. (2022) · Transboundary and Emerging Diseases · doi:10.1111/tbed.14740 · Cited by 26

Reverse genetics systems for SARS-CoV-2: Development and applications

Cai, H.-L., & Huang, Y. (2023) · Virologica Sinica · doi:10.1016/j.virs.2023.10.001 · Cited by 28

Attenuation of SARS-CoV-2 infection by losartan in human kidney organoids

Rahmani, W., Chung, H., Sinha, S., Bui-Marinos, M. P., Arora, R., Jaffer, A., Corcoran, J. A., Biernaskie, J., & Chun, J. (2022) · iScience · doi:10.1016/j.isci.2022.103818 · Cited by 25

Data-driven modelling and prediction of COVID-19 infection in India and correlation analysis of the virus transmission with socio-economic factors

Kumar, A., Rani, P., Kumar, R., Sharma, V., & Purohit, S. R. (2020) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2020.07.008 · Cited by 25

JIB-04 Has Broad-Spectrum Antiviral Activity and Inhibits SARS-CoV-2 Replication and Coronavirus Pathogenesis

Son, J., Huang, S., Zeng, Q., Bricker, T. L., Case, J. B., Zhou, J., Zang, R., Liu, Z., Chang, X., Darling, T. L., et al. (2022) · mBio · doi:10.1128/mbio.03377-21 · Cited by 25

COVID-19 patient serum less potently inhibits ACE2-RBD binding for various SARS-CoV-2 RBD mutants

Junker, D., Dulovic, A., Becker, M., Wagner, T. R., Kaiser, P. D., Traenkle, B., Kienzle, K., Bunk, S., Struemper, C., Haeberle, H. A., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-10987-2 · Cited by 25

Inactivation of aerosolized SARS‐CoV ‐2 by 254 nm UV‐C irradiation

Ruétalo, N., Berger, S., Niessner, J., & Schindler, M. (2022) · Indoor Air · doi:10.1111/ina.13115 · Cited by 25

Neutralization of SARS-CoV-2 Omicron sublineages by 4 doses of the original mRNA vaccine

Xie, X., Zou, J., Kurhade, C., Liu, M., Ren, P., & Shi, P. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111729 · Cited by 26

Potential molecular mechanisms of chronic fatigue in long haul COVID and other viral diseases

Gottschalk, C. G., Peterson, D. L., Armstrong, J., Knox, K. K., & Roy, A. (2023) · Infectious Agents and Cancer · doi:10.1186/s13027-023-00485-z · Cited by 28

The PRRA Insert at the S1/S2 Site Modulates Cellular Tropism of SARS-CoV-2 and ACE2 Usage by the Closely Related Bat RaTG13

Liu, S., Selvaraj, P., Lien, C. Z., Nuñez, I. A., Wu, W. W., Chou, C., & Wang, T. T. (2021) · Journal of Virology · doi:10.1128/jvi.01751-20 · Cited by 24

Discovery of Small-Molecule Inhibitors of SARS-CoV-2 Proteins Using a Computational and Experimental Pipeline

Lau, E. Y., Negrete, O. A., Bennett, W. F., Bennion, B. J., Borucki, M. K., Bourguet, F. A., Epstein, A., Franco, M., Harmon, B., He, S., et al. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.678701 · Cited by 24

The ORF8 Protein of SARS-CoV-2 Modulates the Spike Protein and Its Implications in Viral Transmission

Chou, J.-M., Tsai, J.-L., Hung, J.-N., Chen, I.-H., Chen, S.-T., & Tsai, M. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.883597 · Cited by 24

Influenza Virus-like Particle-Based Hybrid Vaccine Containing RBD Induces Immunity against Influenza and SARS-CoV-2 Viruses

Bommireddy, R., Stone, S., Bhatnagar, N., Kumari, P., Muñoz, L. E., Oh, J., Kim, K., Berry, J. T. L., Jacobsen, K. M., Jaafar, L., et al. (2022) · Vaccines · doi:10.3390/vaccines10060944 · Cited by 24

An immunostimulatory glycolipid that blocks SARS-CoV-2, RSV, and influenza infections in vivo

Tsuji, M., Nair, M. S., Masuda, K., Castagna, C., Chong, Z., Darling, T. L., Seehra, K., Hwang, Y., Ribeiro, Á. L., Ferreira, G. M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39738-1 · Cited by 25

Alkyne as a Latent Warhead to Covalently Target SARS-CoV-2 Main Protease

Ngo, C., Fried, W., Aliyari, S. R., Feng, J. J., Qin, C., Zhang, S., Yang, H., Shanaa, J., Feng, P., Cheng, G., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00810 · Cited by 23

Infectious Clones Produce SARS-CoV-2 That Causes Severe Pulmonary Disease in Infected K18-Human ACE2 Mice

Liu, X., Zaid, A., Freitas, J. R., McMillan, N. A. J., Mahalingam, S., & Taylor, A. (2021) · mBio · doi:10.1128/mbio.00819-21 · Cited by 22

Development of potent and effective synthetic SARS-CoV-2 neutralizing nanobodies

Stefan, M. A., Light, Y. K., Schwedler, J. L., McIlroy, P. R., Courtney, C. M., Saada, E. A., Thatcher, C. E., Phillips, A. M., Bourguet, F. A., Mageeney, C. M., et al. (2021) · mAbs · doi:10.1080/19420862.2021.1958663 · Cited by 25

Structure–Function Analysis of Resistance to Bamlanivimab by SARS-CoV-2 Variants Kappa, Delta, and Lambda

Liu, S., Huynh, T., Stauft, C. B., Wang, T. T., & Luan, B. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.1c01058 · Cited by 22

SARS-CoV-2 can infect human embryos

Montaño, M., Victor, A. R., Griffin, D. K., Duong, T., Bolduc, N., Farmer, A. A., Garg, V., Hadjantonakis, A., Coates, A., Barnes, F. L., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-18906-1 · Cited by 24

Inhibition of major histocompatibility complex-I antigen presentation by sarbecovirus ORF7a proteins

Zhang, F., Zang, T. M., Stevenson, E. M., Lei, X., Copertino, D. C., Mota, T. M., Boucau, J., García-Beltrán, W. F., Jones, R. B., & Bieniasz, P. D. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2209042119 · Cited by 23

Impaired Humoral Immunity to SARS-CoV-2 Vaccination in Non-Hodgkin Lymphoma and CLL PatientsPreprint

Diefenbach, C., Caro, J., Koide, A., Grossbard, M. L., Goldberg, J. D., Raphael, B. G., Hymes, K. B., Moskovits, T., Kreditor, M., Kaminetzky, D., et al. (2021) · medRxiv · doi:10.1101/2021.06.02.21257804 · Cited by 24

Persisting Neutralizing Activity to SARS-CoV-2 over Months in Sera of COVID-19 Patients

Flehmig, B., Schindler, M., Ruétalo, N., Businger, R., Bayer, M., Haage, A., Kirchner, T., Klingel, K., Normann, A., Pridzun, L., et al. (2020) · Viruses · doi:10.3390/v12121357 · Cited by 21

SARS-CoV-2 Variants and Vaccination

Liu, Y., Liu, J., & Shi, P. (2022) · Zoonoses · doi:10.15212/zoonoses-2022-0001 · Cited by 22

IgG-like bispecific antibodies with potent and synergistic neutralization against circulating SARS-CoV-2 variants of concern

Chang, M., Tomasovic, L. M., Kuzmina, N. A., Ronk, A. J., Byrne, P. O., Johnson, R. I., Storm, N., Olmedillas, E., Hou, Y. J., Schäfer, A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33030-4 · Cited by 20

Trim69 is a microtubule regulator that acts as a pantropic viral inhibitor

Song, Y., Nguyen, X.-N., Kumar, A., da Silva, C., Picard, L., Etienne, L., & Cimarelli, A. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2211467119 · Cited by 23

Intranasal delivery of a rationally attenuated SARS-CoV-2 is immunogenic and protective in Syrian hamsters

Liu, S., Stauft, C. B., Selvaraj, P., Chandrasekaran, P., D’Agnillo, F., Chou, C., Wu, W. W., Lien, C. Z., Meseda, C. A., Pedro, C. L., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34571-4 · Cited by 21

Engineering Mice to Study Human Immunity

Sefik, E., Xiao, T., Chiorazzi, M., Odell, I. D., Zhang, F., Agrawal, K., Micevic, G., & Flavell, R. A. (2025) · Annual Review of Immunology · doi:10.1146/annurev-immunol-082523-124415 · Cited by 24

Nanostructures for the Prevention, Diagnosis, and Treatment of SARS-CoV-2: A Review

Kiremitler, N. B., Kemerli, M. Z., Kayacı, N., Karagöz, S., Pekdemir, S., Sarp, G., Sanduvaç, S., Önses, M. S., & Yılmaz, E. (2022) · ACS Applied Nano Materials · doi:10.1021/acsanm.2c00181 · Cited by 21

Monitoring SARS-CoV-2 Infection Using a Double Reporter-Expressing Virus

Chiem, K., Park, J., Vasquez, D. M., Plemper, R. K., Torrelles, J. B., Kobie, J. J., Walter, M. R., Ye, C., & Martínez‐Sobrido, L. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.02379-22 · Cited by 21

Loss of Pfizer (BNT162b2) Vaccine-Induced Antibody Responses against the SARS-CoV-2 Omicron Variant in Adolescents and Adults

Gupta, S. L., Mantus, G. E., Manning, K. E., Ellis, M. L., Patel, M., Ciric, C. R., Lu, A., Turner, J. S., O’Halloran, J. A., Presti, R. M., et al. (2022) · Journal of Virology · doi:10.1128/jvi.00582-22 · Cited by 23

LRRC15 inhibits SARS-CoV-2 cellular entry in trans

Song, J., Chow, R. D.-W., Peña-Hernández, M. A., Zhang, L., Loeb, S. A., So, E. Y., Liang, O. D., Ren, P., Chen, S., Wilen, C. B., et al. (2022) · PLoS Biology · doi:10.1371/journal.pbio.3001805 · Cited by 29

Targeting an evolutionarily conserved “E-L-L” motif in spike protein to identify a small molecule fusion inhibitor against SARS-CoV-2

Jana, I. D., Bhattacharya, P., Mayilsamy, K., Banerjee, S., Bhattacharje, G., Das, S., Aditya, S., Ghosh, A., McGill, A. R., Srikrishnan, S., et al. (2022) · PNAS Nexus · doi:10.1093/pnasnexus/pgac198 · Cited by 21

Increased flexibility of the SARS-CoV-2 RNA-binding site causes resistance to remdesivir

Torii, S., Kim, K. S., Koseki, J., Suzuki, R., Iwanami, S., Fujita, Y., Jeong, Y. D., Ito, J., Asakura, H., Nagashima, M., et al. (2023) · PLoS Pathogens · doi:10.1371/journal.ppat.1011231 · Cited by 23

Induction of interferon response by high viral loads at early stage infection may protect against severe outcomes in COVID-19 patients

Rouchka, E. C., Chariker, J. H., Alejandro, B. S., Adcock, R. S., Singhal, R. A., Ramírez, J. A., Palmer, K. E., Lasnik, A. B., Carrico, R., Arnold, F. W., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-95197-y · Cited by 20

Identifying enhancers of innate immune signaling as broad-spectrum antivirals active against emerging viruses

Maarifi, G., Martin, M. F., Zebboudj, A., Boulay, A., Nouaux, P., Fernandez, J., Lagisquet, J., Garcin, D., Gaudin, R., Arhel, N. J., et al. (2022) · Cell chemical biology · doi:10.1016/j.chembiol.2022.05.009 · Cited by 20

The ACE2-binding Interface of SARS-CoV-2 Spike Inherently Deflects Immune Recognition

Hattori, T., Koide, A., Noval, M. G., Panchenko, T., Romero, L. A., Teng, K. W., Tada, T., Landau, N. R., Stapleford, K. A., & Koide, S. (2020) · Journal of Molecular Biology · doi:10.1016/j.jmb.2020.166748 · Cited by 20

A Comprehensive Analysis of cis-Acting RNA Elements in the SARS-CoV-2 Genome by a Bioinformatics Approach

Ahmed, F., Sharma, M., Al-Ghamdi, A. A., Al-Yami, S. M., Al-Salami, A. M., Refai, M. Y., Warsi, M. K., Howladar, S. M., & Baeshen, M. N. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.572702 · Cited by 22

A Bifluorescent-Based Assay for the Identification of Neutralizing Antibodies against SARS-CoV-2 Variants of Concern In Vitro and In Vivo

Chiem, K., Vasquez, D. M., Silvas, J. A., Park, J., Piepenbrink, M. S., Sourimant, J., Lin, M. J., Greninger, A. L., Plemper, R. K., Torrelles, J. B., et al. (2021) · Journal of Virology · doi:10.1128/jvi.01126-21 · Cited by 18

Vaccination boosts protective responses and counters SARS-CoV-2-induced pathogenic memory B cellsPreprint

Mishra, P. K., Bruiners, N., Ukey, R., Datta, P., Onyuka, A., Handler, D., Hussain, S., Honnen, W. J., Singh, S., Guerrini, V., et al. (2021) · medRxiv · doi:10.1101/2021.04.11.21255153 · Cited by 20

Rapid development of neutralizing and diagnostic SARS-COV-2 mouse monoclonal antibodies

Chapman, A. P., Tang, X., Lee, J. R., Chida, A. S., Mercer, K. B., Wharton, R. E., Kainulainen, M. H., Harcourt, J. L., Martines, R. B., Schroeder, M., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-88809-0 · Cited by 19

Spike Glycoprotein Is Central to Coronavirus Pathogenesis-Parallel Between m-CoV and SARS-CoV-2

Saadi, F., Pal, D., & Sarma, J. D. (2021) · Annals of Neurosciences · doi:10.1177/09727531211023755 · Cited by 17

An optimized high-throughput SARS-CoV-2 dual reporter trans-complementation system for antiviral screening in vitro and in vivo

Li, Y., Tan, X., Deng, J., Liu, X., Liu, Q., Zhang, Z., Huang, X., Shen, C., Xu, K., Zhou, L., et al. (2024) · Virologica Sinica · doi:10.1016/j.virs.2024.03.009 · Cited by 19

Engineering SARS-CoV-2 using a reverse genetic system

Xie, X., Lokugamage, K. G., Zhang, X., Vu, M. N., Muruato, A. E., Menachery, V. D., & Shi, P. (2021) · Nature Protocols · doi:10.1038/s41596-021-00491-8 · Cited by 171

Efficient and modular reverse genetics system for rapid generation of recombinant severe acute respiratory syndrome coronavirus 2

Bae, S., & Myoung, J. (2025) · The Journal of Microbiology · doi:10.71150/jm.2504015 · Cited by 3

Establishment of a reverse genetics system for SARS-CoV-2 using circular polymerase extension reactionPreprint

Torii, S., Ono, C., Suzuki, R., Morioka, Y., Anzai, I., Fauzyah, Y., Maeda, Y., Kamitani, W., Fukuhara, T., & Matsuura, Y. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.09.23.309849 · Cited by 16

A versatile reverse genetics platform for SARS-CoV-2 and other positive-strand RNA viruses

Amarilla, A. A., Sng, J. D. J., Parry, R. H., Deerain, J. M., Potter, J. R., Setoh, Y. X., Rawle, D. J., Le, T. T., Modhiran, N., Wang, X., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23779-5 · Cited by 159

Bacterial Artificial Chromosome Reverse Genetics Approaches for SARS-CoV-2

Chiem, K., Nogales, A., Almazán, F., Ye, C., & Martínez‐Sobrido, L. (2023) · Methods in molecular biology · doi:10.1007/978-1-0716-3533-9_9 · Cited by 1